[1]Cuzick J, Baum M. Tamoxifen and contralateral breast cancer[J]. Lancet, 1985, 2(8449): 282.
[2]Jordan VC.Tamoxifen: a most unlikely pioneering medicine[J].Nat Rev Drug Discov,2003,2(3):205-213.
[3]Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study [J]. J Natl Cancer Inst, 2005, 97(22): 1652-1662.
[4]International Breast Cancer Study Group, Colleoni M, Gelber S, et al. Tamoxifen after adjuvant chemotherapy for premenopausal women with lymph node-positive breast cancer: International Breast Cancer Study Group Trial 13-93[J]. J Clin Oncol, 2006, 24(9): 1332-1341.
[5]Early Breast Cancer Trialists' Collaborative Group, Davies C, Godwin J, et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials [J]. Lancet, 2011, 378(9793): 771-784.
[6]Early Breast Cancer Trialists' Collaborative G. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials [J]. Lancet, 2005, 365(9472): 1687-1717.
[7]Early Breast Cancer Trialists' Collaborative Group. Effects of adjuvant tamoxifen and of cytotoxic therapy on mortality in early breast cancer. An overview of 61 randomized trials among 28,896 women[J]. N Engl J Med, 1988, 319(26): 1681-1692.
[8]Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer [J]. Cochrane Database Syst Rev, 2001(1): CD000486.
[9]芮建中, 张震, 李金恒. 群体药代动力学/群体药效动力学原理及研究方法[J]. 医学研究生学报, 2005, 18(3): 246-249.
[10]Sheiner LB. Learning versus confirming in clinical drug development [J]. Clin Pharmacol Ther, 1997, 61(3): 275-291.
[11]张弨, 赵荣生, 翟所迪, 等. 群体药代动力学概述[J]. 中国临床药理学杂志, 2013, 29(8): 563-565.
[12]ter Heine R, Binkhorst L, de Graan AJ, et al. Population pharmacokinetic modelling to assess the impact of CYP2D6 and CYP3A metabolic phenotypes on the pharmacokinetics of tamoxifen and endoxifen[J]. Br J Clin Pharmacol, 2014, 78(3): 572-586.
[13]Ahmad A, Shahabuddin S, Sheikh S, et al. Endoxifen, a new cornerstone of breast cancer therapy: demonstration of safety, tolerability, and systemic bioavailability in healthy human subjects[J]. Clin Pharmacol Ther, 2010, 88(6): 814-817.
[14]陈冰, 杨婉花, 张伟霞, 等. 中国成年患者万古霉素群体药动学研究[J]. 药学与临床研究, 2013, 21(6): 605-609.
[15]Boeckmann A, Sheiner L, Beal S. NONMEM Users Guide [M]. Part V: 102-103.
[16]凌静, 钱李轩, 丁俊杰, 等. 谷浓度采样设计和算法对群体和个体药动学参数估算的影响[J]. 药学学报, 2014, 49(5): 686-694.
[17]王亚萍, 牛小麟. 基因多态性的研究方法及其临床应用[J]. 临床医学, 2003, 23(9): 49-50.
[18]Pu Z, Zhang X, Chen Q, et al. Establishment of an expression platform of OATP1B1 388GG and 521CC genetic polymorphism and the therapeutic effect of tamoxifen in MCF-7 cells[J]. Oncol Rep, 2015, 33(5): 2420-2428.
[19]Zhang X, Pu Z, Ge J, et al. Association of CYP2D6*10, OATP1B1 A388G, and OATP1B1 T521C polymorphisms and overall survival of breast cancer patients after tamoxifen therapy [J]. Med Sci Monit, 2015, 21: 563-569.
[20]Gao CM, Pu Z, He C, et al. Effect of OATP1B1 genetic polymorphism on the uptake of tamoxifen and its metabolite, endoxifen [J]. Oncol Rep, 2017, 38(2): 1124-1132. |